Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the kidney will produce and secrete erythropoietin to increase the production of red blood cells by targeting CFU-E, proerythroblast and basophilic erythroblast subsets in the differentiation. Erythropoietin has its primary effect on red blood cell progenitors and precursors (which are found in the bone marrow in humans) by promoting their survival through protecting these cells from apoptosis, or cell death.
In this report, we definite one unit for 1ml, except Epoetin-alfa type, which one unit means 10000units/ml
Scope of the Report:
The classification of erythropoietin includes epoetin-alfa, epoetin-beta, darbepoetin-alfa and others. The proportion of epoetin-alfa in 2016 is about 58.53%.
Erythropoietin is widely used for anemia and kidney disorders. The most proportion of Erythropoietin used in Kidney Disorders, and the market share in 2016 is 45.91%.
The worldwide market for Erythropoietin is expected to grow at a CAGR of roughly 5.9% over the next five years, will reach 9640 million US$ in 2024, from 7240 million US$ in 2019, according to a new WMR study.
This report focuses on the Erythropoietin in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Johnson & Johnson
Kyowa Hakko Kirin
LG Life Sciences
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Erythropoietin product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Erythropoietin, with price, sales, revenue and global market share of Erythropoietin in 2017 and 2018.
Chapter 3, the Erythropoietin competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Erythropoietin breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Erythropoietin market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Erythropoietin sales channel, distributors, customers, research findings and conclusion, appendix and data source.